Skip directly to page options Skip directly to A-Z link
Volume 12, Number 6—June 2006
Dispatch

Antiretroviral Drug Resistance and Routine Therapy, Cameroon

Christian Laurent*Comments to Author , Charles Kouanfack†, Laurence Vergne*, Michèle Tardy†, Léopold Zekeng‡§, Nathalie Noumsi†, Christelle Butel*, Anke Bourgeois*, Eitel Mpoudi-Ngolé¶, Sinata Koulla-Shiro†, Martine Peeters*, and Eric Delaporte*
Author affiliations: *Institut de Recherche pour le Développement (UMR 145), Montpellier, France; †Central Hospital, Yaoundé, Cameroon; ‡Laboratoire de Santé et d'Hygiène Mobile, Yaoundé, Cameroon; §National AIDS Program, Yaoundé, Cameroon; ¶Military Hospital, Yaoundé, Cameroon

Main Article

Table

Antiretroviral drug resistance in 21 patients receiving multiple ART in a routine care setting in Cameroon*

Patient no. Age Sex Antiretroviral drugs received Months from start of ART Drug resistance Major genotypic mutations Subtype pol
2-29 46 F 3TC, ZDV, EFV 33 3TC, FTC, EFV, NVP M184V, K103N, P225H CRF02-AG
2-44 49 F 3TC, ZDV, EFV 10 3TC, FTC, EFV, NVP M184V, (K70R), K103N, Y188L CRF02-AG
2-47 42 M 3TC, ZDV, IDV 10 3TC, FTC M184V CRF02-AG
2-59 36 F 3TC, ZDV, EFV, IDV 52 3TC, ZDV, d4T, FTC, EFV, NVP M184V, T215F, (M41L), K103N CRF02-AG
2-66 36 M 3TC, ZDV, d4T, ddI, EFV 21 3TC, FTC, EFV, NVP M184V, K103N CRF02-AG
2-70 30 M d4T, ddI, EFV 6 EFV, NVP K103N CRF02-AG/F
2-75 37 F 3TC, d4T, IDV 9 3TC, FTC M184V A
2-76 34 M 3TC, d4T, EFV 10 3TC, ZDV, d4T, FTC, EFV, NVP M184V, T215Y, K103N F2
2-84 51 M 3TC, ZDV, d4T, ddI, NFV 48 NRTIs, NFV K65R, M184V, Q151M, N88D D
2-91 44 M 3TC, d4T, EFV, IDV 6 EFV, NVP G190E CRF02-AG/F
2-98 32 F d4T, ddI, IDV 7 IDV, RTV V82A D
22-2 42 M 3TC, ZDV, EFV 14 3TC, FTC, EFV, NVP M184I, (M41L), K101E, K103N CRF02-AG
22-9 33 F 3TC, ZDV, d4T, ddI, EFV, IDV 31 3TC, FTC, EFV, NVP M184V, K103N, P225H CRF11-cpx
22-25 30 F 3TC, ZDV, EFV, IDV 18 3TC, FTC M184V CRF02-AG
22-31 42 M 3TC, d4T, IDV 8 3TC, FTC M184V CRF02-AG
22-33 41 F 3TC, ZDV, IDV 18 3TC, FTC M184V CRF02-AG
22-35 58 M 3TC, ZDV, IDV 17 ATV, IDV, RTV V82A CRF01-AE
22-47A 48 F 3TC, ZDV, EFV, IDV 45 3TC, ZDV, d4T, FTC, EFV, NVP M184V, T215F, (D67N, K70R, K219Q), K103N, Y188L CRF02-AG
22-50 32 M 3TC, d4T, NVP 6 3TC, FTC, TDF, (ABC, ddI), EFV, NVP K65R, M184V, Y181C CRF01-AE
22-57 53 M 3TC, ZDV, EFV 7 EFV, NVP K103N CRF02-AG
22I-75 50 F 3TC, ZDV, d4T, ddI, EFV, IDV 29 3TC, ZDV, d4T, FTC, EFV, NVP M184V, T215F, (D67N, K70R, K219E), K103N CRF02-AG

*ART, antiretroviral therapy; 3TC, lamivudine; ZDV, zidovudine; EFV, efavirenz; FTC, emtricitabine; NVP, nevirapine; IDV, indinavir; d4T, stavudine; ddI, didanosine; NFV, nelfinavir; NRTIs, nucleoside reverse transcriptase inhibitors; ATV, atazanavir; RTV, ritonavir; TDF, tenofovir; SQV, saquinavir; ABC, abacavir. Resistances in parentheses indicate possible resistances. Mutations in parentheses indicate thymidine analogue mutations.

Main Article

Page created: January 04, 2012
Page updated: January 04, 2012
Page reviewed: January 04, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external